AstraZeneca (LSE/STO/NYSE: AZN) is discontinuing the eVOLVE-Lung02 Phase III trial after an Independent Data Monitoring Committee (IDMC) concluded that volrustomig plus chemotherapy was unlikely to meet either of its dual primary endpoints — progression-free survival (PFS) or overall survival (OS) — in patients with PD-L1-negative metastatic non-small cell lung cancer (mNSCLC). The trial enrolled 895 patients across 25 countries and was designed to beat Merck's Keytruda (pembrolizumab) plus chemotherapy in a population where immunotherapy delivers its least durable benefit.
The failure is a direct setback for AstraZeneca's ambition to establish volrustomig as a superior first-line option for the mNSCLC patients with low or absent PD-L1 expression. The PD-L1 <1% subgroup — the primary analysis population — is widely regarded as the hardest to treat with existing checkpoint inhibitors, and the rationale for testing a dual-checkpoint bispecific in this setting was mechanistically coherent: volrustomig is engineered to simultaneously block PD-1 and CTLA-4 on the same activated T cell, concentrating CTLA-4 inhibition where it is most needed while sparing resting peripheral T cells. The IDMC's futility call suggests that coordinated dual blockade on the same T cell did not translate into a survival advantage over pembrolizumab plus chemotherapy in this population.
No numerical efficacy data were disclosed. AstraZeneca said the safety profile of volrustomig plus chemotherapy was consistent with the known profiles of the individual agents, with no new safety signals identified. The 895-patient trial randomized patients to volrustomig plus chemotherapy or pembrolizumab plus chemotherapy, followed by maintenance with the respective checkpoint inhibitor. Secondary endpoints covered PFS and OS in the broader intent-to-treat population (PD-L1 <50%), but the IDMC's recommendation was based on futility in the PD-L1 <1% primary analysis population.
The result adds to recent difficulty in improving on pembrolizumab-based regimens in first-line NSCLC. Immutep discontinued the Phase III TACTI-004 trial of LAG-3 agonist eftilagimod alfa plus pembrolizumab and chemotherapy in first-line NSCLC in March 2026 after an interim futility analysis. Bristol Myers Squibb's Opdivo (nivolumab) plus Yervoy (ipilimumab) with chemotherapy remains approved in this population, as does AstraZeneca's own Imjudo (tremelimumab) plus Imfinzi (durvalumab) plus chemotherapy — the latter approved in November 2022 under the POSEIDON regimen. The eVOLVE-Lung02 result raises questions about whether a bispecific format delivering simultaneous PD-1/CTLA-4 blockade on the same T cell offers a clinically meaningful advantage over sequential or separate checkpoint combinations in the chemotherapy-combination setting.